

Originalarbeiten

Walter Weber

1. **Weber W.:** Zur funktionellen Morphologie des menschlichen Ovariums nach Absetzen von Östrogen-Gestagen-Kombinationspräparaten. Geburtshilfe und Frauenheilkunde 29: 149-159, 1969.
2. Mall-Haefeli M., Ludwig K.S., Keller M. und **Weber W.:** Beitrag zum Wirkungsmechanismus der oralen Ovulationshemmer beim Menschen. Zeitschrift für Geburtshilfe und Gynäkologie 171: 1-12, 1969.
3. Groff P., Torhorst J., Speck B., Nissen C., **Weber W.**, Cornu P., Rossier J. und Biland L.: Die Graft-versus-Host-Krankheit, eine wenig bekannte Komplikation der Bluttransfusion. Schweiz. med. Wschr. 106: 634-639, 1976.
4. Cornu P., Groff P., **Weber W.**, Nissen C., Burri H.P. und Speck B.: Thrombozytenerersatz mit HL-A-typisierten nichtverwandten Einzelspendern. Schweiz. med. Wschr. 106: 889-893, 1976.
5. **Weber W.**, Fishenfeld J. und Desser K.B.: Pneumomediastinum und Mediastinitis, seltene Komplikationen eines Lungenabszesses. Schweiz. med. Wschr. 106: 994-997, 1976.
6. **Weber W.** and Ulrich J.: Multiple sclerosis, diffuse lymphoplasmocytic encephalitis and Alzheimer's disease in a patient with progressive dementia European Neurology 14: 241-249, 1976.
7. **Weber W.**, Speck B., Cornu P., Nissen C., Groff P., Burri H.P. und Buckner C.D.: Failure of isogeneic marrow engraftment in a patient with acute leukemia. Acta haematologica 56: 338-344, 1976.
8. Nagel G.A., Sauer R., Herbst M., **Weber W.**, Halter K. und Albrecht R.: Das Verhalten einzelner Immunparameter bei Patientinnen mit lokoregional begrenztem Mammakarzinom. Schweiz. med. Wschr. 107: 1007-1009, 1977.
9. **Weber W.**, Nagel G.A., Obrist R., Nagel E., Heitz Ph., Oberholzer M. und Herzig D.: Differenzierung von Lymphozytenpopulationen im Blut bei Patientinnen mit Mammakarzinom. Schweiz. med. Wschr. 107: 1010-1012, 1977.
10. Nissen C., Cornu P., **Weber W.** und Speck B.: Differentialdiagnose der primären und sekundären Erythrozytosen mit Hilfe der in-vitro-Kultur hämopoetischer Vorläuferzellen. Schweiz. med. Wschr. 41: 1581-6583, 1978.
11. **Weber W.**, Nagel G.A., Nagel-Studer E. und Albrecht R.: Effects of chemotherapy on the immune system, special reference to adriamycin and vincristine. In: Cell-Sepa-

- ration and Cryobiology, Selected Papers of an International Symposium in Vienna (9.-12.11.1977), F.K. Schattauer-Verlag, Stuttgart-New York, pp 51-56, 1978.
12. Hug J., Gudat F., Speck B., **Weber W.** und Wey W.: Die Angiolimmunoblastische Lymphadenopathie. HNO 27: 25-28, 1979.
 13. Hug J., Gudat F., **Weber W.** und Wey W.: Die Angio-Immunoblastische Lymphadenopathie. Sonderdruck "Aktuelle Probleme der ORL 2". Hrsg. B. Kellerhals et al. Verlag H. Huber, Bern, 1979.
 14. Speck B., Sartorius J., Cornu P., Nissen C., **Weber W.** und Gratwohl A.: Knochenmarkstransplantation bei schwerer aplastischer Anämie und akuter Leukämie. Onkologie 2: 79-82, 1979.
 15. Cornu P., Speck B., **Weber W.**, Sartorius J., Groff P.: The pattern of hesopoietic reconstitution after ALG and bone marrow infusion in severe aplastic anaemia. In: Bone Marrow Transplantation in Europe. J.L. Touraine (Hrsg.). Excerpta Medica Amsterdam, pp. 3-8, 1979.
 16. **Weber W.**, Nagel G.A., Nagel E. und Albrecht R.: Vincristine infusion. A phase I study. Cancer Chemotherapy and Pharmacology 3: 495-5, 1979.
 17. **Weber W.**, Torhorst J. und Obrecht J.P.: Die Epidemiologie des Pankreaskarzinoms in Basel. Schweiz. med. Wschr. 110: 857-860, 1980.
 18. **Weber W.**, Gudat F., Braun L. and Obrecht J.P.: Immunoblastische Lymphadenopathie. Klinisch- pathologische Konferenz. Schweiz. Rundschau Med. (PRAXIS) 69: 387-400, 1980.
 19. **Weber W.**, Müller H.J., Moroni C., von Fliedner V., Sartorius J.A., Speck B., Obrecht J.P. and Jeannet M.: Two siblings with azute-T-Cell Lymphocytic Leukemia. Int. J. Cancer 26: 557-564, 1980.
 20. Huber P.:R., Hagmaier V., Scholer A., Vogt H., **Weber W.**, Linder E., Viollier E. and Rutishauser G.: Different radioimmunoassays (RIA) in comparison to the enzyme test for prostatic acid phosphatase (PAP) in the diagnosis of the prostatic carcinoma. Urological Research 8: 246, 1980.
 21. Biedermann C., **Weber W.**, Rist M. and Scholer A.: La determination biochimique des taux de phosphatase acide dans la moelle osseuse et le plasma et leur relation avec les stades du cancer de la prostate. Helv. chir. Acta 47: 431-434, 1980.
 22. **Weber W.**, Tackmann W., Freund H.J., Kaeser H., Obrist R. and Obrecht J.P.: The evaluation of neurotoxicity in cancer patients treated with vinca alkaloids with special reference to vindesine. Anticancer Research 1: 31-34, 1981.
 23. Joss R., Goldhirsch A., Cavalli F., **Weber W.**, Kaplan S., Obrecht J.P., Sonntag R., Brunner K.W.: Chemotherapie des nichtkleinzelligen Bronchuskarzinoms mit einer Kombination von Cis-Diamminedichloroplatinum (II) und VP 16-213. Schweiz. med. Wschr. 111: 1331-1334, 1981.

24. **Weber W.**, Tackmann W., Ludwig C., Egger R. and Obrecht J.P.: Vindesine 24-h infusion. Phase I study. In: W. Brade., G.A. Nagel and S. Seeber (Eds.) Proceedings of the International Vinea Alkaloid Symposium - Vindesine. S. Karger, Basel: pp. 72-77, 1981.
25. Gratwohl A., Tschan M., Dalquen P., **Weber W.**: Klinisch-pathologische Konferenz. Polyzythämie. Schweiz. Rundschau Med. (PRAXIS) 70: 767-775, 1981.
26. Obrecht J.P., **Weber W.**, Cano J.P., Crevoisier Ch., Alberto P., Forgo I., Heintz R. and Germano G.H.: 5-Fluorouracil: A comparative pharmacokinetic study and preliminary results of a clinical phase I study. Recent Results in Cancer Research 79: 101-107, 1981.
27. **Weber W.** and Obrecht J.P.:Thymostimulin (TP-1). Phase I study with a new immunomodulator. Eur. J. Cancer Clin. Oncol. 17: 942-943, 1981.
28. Rutishauser G., Hagmaier V., **Weber W.** und Huber P.R.: Radioimmunoassay (RIA) und enzymatische Bestimmung der sauren Prostataphosphatase (SSP) im Serum und im Knochenmarkspunktat bei Patienten mit Prostatakarzinom. In: Verhandlungsbericht der Deutschen Gesellschaft für Urologie, 32. Tagung (1980), Springer Verlag, Berlin-Heidelberg, New York, pp. 106-109, 1981.
29. Metzger U., Aeberhard P., Egeli R. A., Harder F. , LargiadAr F., Müller W., Pettavel J., **Weber W.** and Cavalli F.: Adjuvante portale Leberperfusion beim kolorektalen Karzinom. Eine schweizerische Multizenterstudie. Helv. Chir. Acta 49: 175-178, 1982.
30. **Weber W.** und Müller Hj.: Familiäre Tumorkrankheiten - genetisch bedingt? Hexagon Roche II, Nr. 2, pp. 1-5, 1983.
31. **Weber W.**, Meier K., Obrecht J.P. und Torhorst J.: Die Epidemiologie des Magenkarzinoms in Basel. Schweiz. med. Wschr. 113: 567-569, 1983.
32. Gencik A., **Weber W.** und Müller Hj.: Genetische Familienberatung bei Mammakarzinom. Inform. Arzt Jg. 11, 7: 33-37, 1983.
33. **Weber W.**, Arnold H., Drings P., Germano G., Müller K.M., Queisser W., Weshershausen M. und Obrecht J.P.: Etreinat (RO 109359, Tigason) + CCNU (1-(2-chloroäthyl)-3-cyclohexy-1-1-nitroso-urea) + Bleomycin versus CCNU + Bleomycin in der Behandlung des fortgeschrittenen Plattenepithel-Karzinoms des Bronchus (AIO-Studie BS 1/78). Onkologie 6: 62 - 65, 1983.
34. **Weber W.**, Obrecht J.P.: Etreinate, Lomustine and Bleomycin Versus Lomustine and Bleomycin in advanced squamous cell lung carcinoma. Cancer Treatment Reports 67: 847-849, 1983.
35. **Weber W.**: Vindesine. A toxicology study. Verh. Dtsch. Krebs Ges. 3: 571, 1982.
36. **Weber W.**, Hans K., Labedzki L., Schroeder M. and Obrecht J.P.: Cisplatin and VP-16-213 in advanced squamous cell lung cancer. A phase I/II study. Proceedings of

- the 13th International Congress of Chemotherapy, Verlag H. Egermann, Vienna, Tom 15, Part 281: pp. 125-127, 1983.
37. Remagen W., Oberholzer M., Mihatsch J., Schilt R., Perret E., **Weber W.** und Misteli D.: Osteosarkome des postcranialen Skeletts (eine retrospektive Studie unter Mitwirkung von 38 Instituten und Kliniken). Verh. Dtsch. Ges. Path. 67: 639, 1983.
 38. **Weber W.** und Muller Hj.: Os factores geneticos nas doencas malignas familiares. Hexagono Roche, Ano 11, Nj. 3, p. 1-7, 1984.
 39. **Weber W.**, Obrecht J.P.: Erste klinische Erfahrungen mit Thymostimulin (TP-1). In: Immundefizienzen. IV. Freiburger Kolloquium. Hrsg:- G. Löhr. Attempto Verlag, Tübingen, Deutschland, S. 7184, 1984. .
 40. Kovacs E., **Weber W.** and Müller Hj.: Age-related variation in the DNA-repair synthesis after UV-C irradiation in unstimulated lymphocytes of healthy blood donors Mutation Research 131: 231-237, 1984.
 41. Hehlmann R., Erfle V., Schetters H., Inz A., Rohmer H., Schreiber M.A., Pralle H., Essers U. and **Weber W.**: Antigens and circulating immune complexes related to the primate retroviral glycoprotein SiSVgp 70. Indicators of early mortality in human acute leukemias and chronic myelogenous leukemias in blast crisis. Cancer 54: 2927-2935, 1984.
 42. Hehlmann R., Kreeb G., Schreiber M.A., **Weber W.**, Obrecht J.P., Bichl T., Gössner W., und Erfle V.: Mögliche Diagnose maligner Lymphome und Sarkome durch tumorvirusspezifische Antigene und Antikörper im Serum. Verhandlungen der Deutschen Gesellschaft für Innere Medizin 90: 10361039, 1984.
 43. Akerto P., Mermillod B., **Weber W.** and Cavalli F.: A randomized trial comparing 5-fluorouracil and 5' Deoxy-5-fluorouridine. Drug dose, hematologic and non-hematologic toxicity. Cancer Immunology Immunotherapy. Suppl. to Vol 18: 5, 1984.
 44. Metzger U., Mermillod B., Aeberhard P., Egeli R., Laffer U., Martinoli S., Müller W., Schroeder R., Cavalli F., **Weber W.** and the Swiss Group for Clinical Cancer Research: Adjuvant portal liver infusion with 5-fluorouracil and mitomycin C following curative large bowel cancer surgery. In: Adjuvant Therapy of Cancer IV, Eds.: S.E. Jones and S.E. Salmon, Grune & Stratton Inc., Orlando, pp. 471-478, 1984.
 45. Alberto P., Abele R., Mermillod B., **Weber W.** and Cavalli F.: Phase I, II and III trials of intravenous 5'Deoxy-5-Fluorouridine. In: K. Kimura, S. Fujii, M. Ogawa, G.B. Bodey, P. Alberto, eds. Fluoropyrimidines in Cancer Therapy. Elsevier Science Publishers B.V. 1984.
 46. Hehlmann R., Schreiber M.A., Kreeb G., Erfle V., **Weber W.** and Obrecht J.P.: Discrimination of leukemias, lymphomas, and non-neoplastic controls by retroviral serum markes. Haematology and Blood Transfusions 29: 207-214, 1985.
 47. Müller Hj., Bürki N., Gencik A., Gencikova A., Kovacs E., Roth M., Trächslin N., Voegtli B. und **Weber W.**: Familiäre Tumorkrankheiten. Erste Ergebnisse einer Erhebung über ihr Vorkommen in Basel. Sozial- und Präventivmedizin 30: 28-32, 1985.

48. **Weber W.**, Honegger H.P., Forrer P., Obrecht J.P., Ryssel H.J., Siegenthaler P. und Cavalli F.: Das inoperable Pankreaskarzinom. Versuch einer Phase II Studie mit Doxifluridin in der SAKK. Konsequenzen für zukünftige Chemotherapiestudien. SAKK Bulletin Jahrgang 5, Nr. 2: 22-23, 1985.
49. **Weber W.**, Voegtli B., Buser M., Gencik A., Kayasseh L., Stalder G.A., Torhorst J. und Müller Hj.: Vergleich der Tumorinzidenz bei 251 Verwandten ersten Grades von 50 Patienten mit kolorektalen Karzinomen mit derjenigen der Basler Bevölkerung. Schweiz. med. Wschr. 115: 10051006, 1985.
50. **Weber W.**: The need for pilot studies and surgery only controls in adjuvant therapy trials for large-bowel cancer. Recent Results in Cancer Research 98: 126-129, 1985.
51. Müller Hj., Gencik A. and **Weber W.**: Preferential occurrence of leukemias and malignant lymphomas in families of patients with Hodgkin's disease. Revue de l'Institut de Pasteur de Lyon 1-2: 136, 1985.
52. **Weber W.**: The potential of family registries for research, detection and prevention. Sozial- und Präventivmedizin 31: 97, 1986.
53. Gencik A., Almendral A.C., Ludwig H., Weber W. und Müller Hj.: Zur Heterogenität des Mammakarzinoms. Sozial- und Präventivmedizin 31: 221223, 1986.
54. **Weber W.**: The potential of the familial cancer registry for anticancer research and medical practice. Anticancer Research 6: 701-704, 1986.
55. Kovacs E., Stucki D., **Weber W.** and Müller Hj.: Impaired DNArepair synthesis in lymphocytes of breast cancer patients. Eur. J. Cancer Clin. Oncol. 22: 863-869, 1986.
56. **Weber W.**, Gencik A. and Müller Hj.: Familial Cancer - Consequences for the oncological practice. Cancer Detection and Prevention 9: 455458, 1986.
57. Wils 3., Bleiberg H., Dalesio O., Duez N., Blijham G., Planting A., Splinter T. and **Weber W.**: An EORTC gastrointestinal group phase II evaluation of epirubisin combined with 5-fluorouracil in advanced adenosarcoma of the pancreas. Eur. J. Cancer Clin. Oncol. 23: 10171018, 1987.
58. **Weber W.**, Almendral A.C., Buser M., Gencikova A., Gencik A., Ludwig H., Obrecht J.P., Torhorst J. und Müller Hj.: In den Familien von Ovarialkarzinompatientinnen sind Mammakarzinome bei den Frauen und kolorektale Karzinome bei den Männern übervertreten. Geburtsh. u. Frauenheilk. 47: 460-462, 1987.
59. Metzger U., Mermillod B., Aeberhard P., Gloor F., Bissat A., Egeli R., Laffer U., Martinoli S., Müller W., Schroeder R. and **Weber W.**: Intraportal chemotherapy in colorectal carcinoma as an adjuvant modality. World J. Surg. 11: 452-458, 1987.
60. Gencik A., Buser M., Temminck B., Obrecht J.P., **Weber W.** and Müller Hj.: High incidence of stomach cancer in relatives of patients with malignant lymphoproliferative disorders. Cancer Detection and Prevention Suppl. 1: 121-125, 1987.

61. Bürki N., Gencik A., Torhorst J., **Weber W.** and Müller Hj.: Familial and histological analyses of 138 breast cancer patients. *Breast Cancer Research and Treatment* 10: 159-167, 1987.
62. Bosshard R., Buser M., **Weber W.**, Müller Hj.: Zur Ökogenetik des Basalioms. *Schweiz. Rundschau Med. (PRAXIS)* 77: 185-187, 1988.
63. Alberto P., Mermillod B., Germano G., Kaplan S., **Weber W.**, Joss R., Späti B., Martz G. and Cavalli F.: A randomized comparison of doxifluridine and fluorouracil in colorectal carcinoma. *Eur. J. Clin. Oncol.* 24: 559-563, 1988.
64. Senn H.P., Trân-Thang C., Wodnar-Filipowicz A., Jiricny J., Fopp M., Gratwohl A., Signer E., **Weber W.**, Moroni Ch.: Mutation analysis of the N-ras proto-oncogene in active and remission phase of human leukemia. *Int. J. Cancer* 41: 59-65, 1988.
65. **Weber W.**, Dolder A., Feinstein R., Moser U. und Akovbiantz A.: Charakteristika des hereditären kolorektalen Karzinoms ohne vorbestehende Polypose, aufgezeigt anhand von zwei Familien. *Schweiz. med. Wschr.* 118: 777-780, 1988.
66. Schlossberg D., **Weber W.**, Stoffel U., Henggeler K., Stocker H., Föppl M. und Akovbiantz A.: Periampullary, colorectal and gastric cancer in two siblings. *Int. J. Cancer* 42: 839-841, 1988.
67. Laffer U., Jäggi P., Harder F., Metzger U., Ereli R., **Weber W.**, Barras L.P., Schweizer W., Müller W., Martinoli S., von Huben R., Arma S.: Bluttransfusionen und die Prognose nach kurativer Resektion kolorektaler Karzinome: Besteht eine Assoziation? *Helv. chir. Acta* 56: 461-464, 1989.
68. Bürki N., Buser M., Emmons L.R., Gencik A., Häner M., Torhorst J., **Weber W.**, Müller Hj.: Malignancies in families of women with medullary, tubular and invasive ductal breast cancer. *Eur. J. Cancer* 26: 295-303, 1990.
69. Borner M., Laffer U., Ludwig C., Obrist R., Metzger U., Aeberhard P., **Weber W.**, Castiglione M., Obrecht J.P., Brunner K., Gloor F., Cavalli F. and Senn H.J.: Effectiveness and low toxicity of hepatic artery infusion with fluorouracil and mitomycin for metastatic colorectal cancer confined to the liver. *Ann. Oncol.* 1990; 1: 227-228.
70. **Weber W.**, Föppl M., Schlossberg D., Locher K.: Manifestations of hereditary colorectal cancer. *Anticancer Research* 10: 543-546, 1990.
71. The International Breast Cancer Study Group. **Weber W.** as one of the coauthors: Late effects of adjuvant oophorectomy and chemotherapy upon premenopausal breast cancer patients. *Annals of Oncology* 1: 30-35, 1990.
72. The International Breast Cancer Study Group. **Weber W.** as one of the coauthors: Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. *J. Clin. Oncol.* 1990; 8: 519-526.

73. Möller R., Torhorst J.K.H., Dirschmid K., Buser M., **Weber W.** und Müller H.J.: Inzidenz und Spektrum von Tumorkrankheiten bei Verwandten 1. Grades von Magenkarzinompatienten. Schweiz. med. Wschr. 1990; 120: 936-940.
74. International (Ludwig) Breast Cancer Study Group. **Weber W.** as one of the coauthors: Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 1990; 335: 1565-1568.
75. Nosedà G., **Weber W.**: Die Tätigkeit der Schweizerischen Krebsliga in der Krebsbekämpfung. Schweiz. med. Wschr. 1990; 120: 1159-1165.
76. Knüsli C., Ruff P., Laffer U., Stoll H.R., Obrist R., **Weber W.** and Obrecht J.P.: Intra-peritoneal chemotherapy in peritoneal malignancy: impact of intensive system care on practicability. Acta Medica Austriaca 16: 70-73, 1989.
77. Stoll H.R. und **Weber W.**: Onkologiepflege: auch zu Hause! Krankenpflege 12/90: 54-58, 1990.
78. **Weber W.**, Mosimann S., Meyer B., Müller H. und Stalder G.A.: Bedeutung der Familienanamnese bei kolorektalem Karzinom. Deutsche Medizinische Wochenschrift 115: 1859-1862, 1990.
79. **Weber W.**, Metzger U., Laffer U. and Egeli R.: Hematological toxicity of adjuvant portal liver infusion with fluorouracil, mitomycin and heparin. Anticancer Research 11: 365-368, 1991.
80. Laffer U., Metzger U., Aeberhard P., Ariqoni M., Arma S., Barras J., Egeli R., Martinoli S., Müller W., Schweizer W., **Weber W.**, Pampalona S. und die SAKK: Endauswertung der randomisierten Multizenter-Studie SAKK 40/81: Adjuvante portale Chemotherapie beim kurativ resezierten kolorektalen Karzinom. Helv. chir. Acta 58, 755-758, 1991.
81. **Weber W.**, Bartling D. und Stoll H.: Spitalexterne Onkologiepflege in Basel. Erfahrungsbericht über die ersten vier Jahre. Schweiz. Aerztezeitung 5: 129-131, 1992.
82. **Weber W.**: Atembeschwerden bei Krebskrankheiten - Ursachen und Behandlung. Schweiz. Rundschau (PRAXIS) 81: 20-22, 1992.
83. **Weber W.**, Mosimann S. und Müller H.J.: Die Bedeutung der Familienanamnese bei Frauen mit Mammakarzinom. Schweiz. Med. Wschr. 122: 345-347, 1992.
84. **Weber W.**: Krebsforschung in der Praxis. Der aufmerksame Arzt und die Familienanamnese. Schweiz. Rundschau Med. (PRAXIS) 81: 1069-1073, 1992.
85. Müller H.J., Mosimann S., Gebhardt M., Scott R.J., Spycher M. and **Weber W.**: Tumorkrankheiten in den Familien von 600 Mammakarzinompatientinnen unter besonderer Berücksichtigung der familiären Adenokarzinomatose und des Li-Fraumeni -/SBLA-Syndroms. Helv. chir. Acta 59: 239-245, 1992.
86. **Weber W.**: Cancer control by family history. Anticancer Research 13: 1197-1202, 1993.

87. Scott R.J., Krummenacher F., Mary J.L., **Weber W.**, Spycher M., Müller H.J.: Vererb-
bare p53-Mutation bei einem Patienten mit Mehrfachtumoren; Bedeutung für die ge-
netische Beratung. Schweiz. Med. Wschr. 123: 1287-1292, 1993.
88. Kubba S.V., **Weber W.**, Mehta J.P.: Familial occurrence of cancer in Basel city. Indian
Journal of Cancer 30: 100-118, 1993.
89. **Weber W.**, Laffer U., Metzger U. and SAKK: Adjuvant portal liver infusion with 5-fluo-
rouracil and mitomycin in colorectal cancer. Anticancer Research 13: 1839-1840,
1993.
90. Hehlmann R., Heimpel H., Hasford J. and 47 further authors (incl. **Weber W.**): Ran-
domized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia:
prolongation of survival by hydroxyurea. Blood 82: 389-407, 1993.
91. **Weber W.** und Möller R.: Stomach cancer in the families of patients with cancer. Eur.
Journal of Cancer Prevention 3 (Suppl.): 105, 1994.
92. The International Breast Cancer Study Group with **Weber W.** as one of the co-
authors: Timing of baseline quality of life assessment in an international adjuvant
breast cancer trial: 1st effect on patient self estimation. Annals of Oncology 5: 65-74,
1994.
93. Mary J-L., Bishop T., Kolodner R., Lipford J., Kane M., **Weber W.**, Torhorst J., Müller
H.J., Spycher M., Scott R.: Mutational analysis of the hMSH2 gene reveals a three
base pair deletion in a family predisposed to colorectal cancer development. Human
Molecular Genetics, 3: 2067-2069, 1994.
94. Roth M., Rogers S., Roberts S.S., Boyle J.M., Müller H.J. and **Weber W.**: Stimulation
of UV-induced DNA excision repair by chemotherapeutic drugs in cancer patients.
Anticancer Research 14: 809-816, 1994.
95. Fürstenberger G., Christen H., Minder Ch.E., Spycher M. and **Weber W.**: Breast
cancer in first degree relatives of 180 female breast cancer patients. in vivo 8: 367-
370, 1994.
96. Müller H.J., Scott R., **Weber W.** and Meier R.: Colorectal cancer: lessons for genetic
counselling and care for families. Clin Genet 46: 106-114, 1994.
97. Orth H.B., Hurwitz N., Lohri A., **Weber W.** and Herrmann R.: γ -Schwerketten-Pro-
duktion als Epiphänomen bei Non-Hodgkin-Lymphom. Dtsch.med.Wschr. 119: 1235-
1238, 1994.
98. Buerstedde J-M., Alday P., Torhorst J., **Weber W.** and Müller H., Scott R.: Detection
of new mutations in six out of 10 Swiss HNPCC families by genomic sequencing of
the hMSH2 and hMLH1 genes. Journal Med. Genet 32: 909-912, 1995.
99. **Weber W.**, Maibach R., Laffer U., Metzger U., Egeli R., Lorenz M., Aeberhard P.,
Dupont-Lampert V., Nöthiger F., Rüedi Th. and Castiglione M. for the Swiss Group
for Clinical Cancer Research: Early hematological toxicity of adjuvant perioperative

- intraportal and intravenous chemotherapy with fluorouracil, mitomycin and heparin in colorectal cancer. *Anticancer Research* 15: 2197-2200, 1995.
100. **Weber W.:** Dr.med. h.c. Heinrich Rellstab, Pionier der medizinisch-genealogischen Forschung in der Schweiz. *Therapeutische Umschau*, 52: 790-791, 1995.
 101. SAKK (**Weber W.** as one of the coauthors): Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. *Lancet*, 345: 349 - 353, 1995.
 102. Garvin A., Spycher M., Häner M., Torhorst J., Müller H., Herrmann R., Rochlitz Ch., **Weber W.**, Scott R.: BRCA1 mutations in a selected series of breast / ovarian cancer patients. *Journal of Medical Genetics*, 33: 721 - 725, 1996.
 103. The International Breast Cancer Study Group. **Weber W.** as one of the coauthors: Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. *Lancet* 347: 1279 - 1284, 1996.
 104. The International Breast Cancer Study Group. **Weber W.** as one of the coauthors: Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. *J. Clin. Oncol.* 14: 1885-1894, 1996.
 105. Hehlmann R., Heimpel H., Hossfeld D.K., and 19 authors and the German CML Study Group (**Weber W.** as a participant): Randomized study of the combination of hydroxyurea and interferon alpha vs hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML study II): outline and goals. *Bone Marrow Transplantation* 17, Suppl. 3.: 21-24, 1996.
 106. Hehlmann R., Ansari H., Hanford J. and 8 authors and the German CML Study Group (**Weber W.** as a participant): Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. *British Journal of Haematology* 97: 76-85, 1997.
 107. Reiter A., Skladny H., Hochhaus A. and 5 authors and the German CML Study Group (**Weber W.** as a participant): Molecular response of CML patients treated with interferon- α monitored by quantitative Southern blot analysis. *British Journal of Haematology* 97: 86-93, 1997.
 108. The International Breast Cancer Study Group. **Weber W.** as one of the coauthors: Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients: *J. Clin. Oncol.* 15: 1385-1394, 1997.
 109. Heinimann K., Müller H., **Weber W.** and Scott R.J.: Disease expression in Swiss hereditary non-polyposis colorectal cancer (HNPCC) kindreds. *Int. J. Cancer (Pred. Oncol.)* 74: 281-285, 1997.
 110. Goldhirsch A., Gelber R.D., Castiglione M. and 14 coauthors + International Cancer Study Group. **Weber W.** as one of further coauthors: Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: Results of the International Breast Cancer Study Group (IBCSG) Trial VI. *Ann. Oncol.* 8: 751-756, 1997.

111. Hürny C., Bernhard J., Coates A.S. and 9 coauthors for the International Breast Cancer Study Group. **Weber W.** as one of further coauthors: Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. *Lancet* 347: 1279-1284, 1997.
112. Peltomaki P., Vasen H.F.A. and The International Collaborative Groups on Hereditary Nonpolyposis Colorectal Cancer. **Weber W.** as one of the coauthors: Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. *Gastroenterology* 113: 1146-1158, 1997.
113. Heinimann K., Müller H., **Weber W.** and Scott R.J.: Disease expression in Swiss hereditary non-polyposis colorectal cancer (HNPCC) kindreds. *Int. J. Cancer (Pred. Oncol.)* 74: 281-285, 1997
114. Heinimann K. Müllhaupt B., **Weber W.**, Attenhofer M., Scott R.J., Fried M., Martinoli S., Müller H. And Dobbie Z.: Phenotypic differences in familial adenomatous polyposis based on APC gene mutation status. *Gut* 43: 675-679, 1998.
115. Borner M.M., Castiglione M., Bacchi M., **Weber W.**, Herrmann R., Fey M.F., Pagani O., Leyvraz S., Morant R., Pestalozzi B., Hanselmann S. and Goldhirsch A. for the SAKK: The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: Results of a phase III trial. *Annals of Oncology* 9: 535-541, 1998.
116. Mussio P., **Weber W.**, Brunetti D., Stemmermann G.N. and Torhorst J.: Taking a family history in cancer patients with a simple questionnaire. *Anticancer Research* 18: 2811-2814, 1998.
117. Heinimann K., Scott R. J., Chappuis P., **Weber W.**, Müller H., Dobbie Z. and Hutter P.: N-acetyltransferase 2 influences cancer prevalence in hMLH1/hMSH2 mutation carriers: *Cancer Research* 59: 3038-3040, 1999.
118. Heinimann K., Scott R. J., Buerstedde J.-M., **Weber W.**, Siebold K., Attenhofer M., Müller H., Dobbie Z.: Influence of selection criteria on mutation detection in patients with hereditary nonpolyposis colorectal cancer: *Cancer* 85: 2512-2518, 1999.
119. Hehlmann R., Hochhaus A., Kolb H.-J. and 19 authors for the German CML-Study Group and the SAKK (**Weber W.** as a participant): Interferon – α before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure: *Blood*, 94: 3668-3677, 1999.
120. Crivellari D., Bonetti M., Castiglione-Gertsch M. and 18 authors for the International Breast Cancer Study Group (**Weber W.** as a participant): Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII: *J. Clin. Oncol.*, 18: 1412-1422, 2000.
121. Bedwani R., Abdel-Fattah M., El-Shazly M., Bassili A., Zaki A., Abu Seif H. and **Weber W.**: Profile of familial breast cancer in Alexandria, Egypt. *Anticancer Research* 21: 3011-3014, 2001.

122. **Weber W.**, Estoppey J. and Stoll H.: Familial cancer diagnosis. *Anticancer Research* 21: 3631-3636, 2001.
123. Landolfi R., Marchioli R., Kutti J., Gisslinger H., Tognoni G., Patrono C., and Barbui T. for the European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators (**Weber W.** as a participant): Efficacy and safety of low-dose aspirin in polycythemia vera, *N. Engl. J. of Med.*, 350: 114-124, 2004.
124. Rapley E.A, Hockley S., Warren W. and 36 co-authors (**Weber W.** as a co-author): Somatic mutations of KIT in familial testicular germ cell tumors. *Br J Cancer* 90: 2397 – 2401, 2004.
125. **Weber W.** de Sabata M.S., Paredes R. M.M., Rodriguez G., Santos C., Sabillon J.U. and Zwahlen M.: Cancer in first degree relatives of latin american women with cancer. A pilot study. *Anticancer Research* 25:1219-1224, 2005.
126. **Weber W.** and Scott R.J. : Case report: Familial gastric cancer and chordoma in the same family. *Hereditary Cancer in Clinical Practice* 3:81-84, 2005.
127. Nathanson K.L., Kanetsky P.A., Hawes R. and 46 co-authors (**W.Weber** as a co-author): The Y deletion gr/gr and susceptibility to testicular germ cell tumor. *Am J Hum Genet.* 77: 1034-1043, 2005.
128. Crockford G.P., Linger R., Hockley S. and 40 co-authors (**W.Weber** as a co-author): Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. *Hum Mol Genet* 15: 443-451, 2006.
129. 126. Pichert G., Bolliger B., Buser K., Pagani O., Swiss Institute for Applied Cancer Research Network for Cancer Predisposition Testing and Counseling.
130. **Weber W.** as a member of the network: Evidence-based management options for women at increased breast/ovarian cancer risk. *Ann Oncol.* 1 : 9-19, 2003.
131. Marchioli R., Finazzi G., Landolfi R., Kutti J., Gisslinger H., Patrono C., Marilus R., Villegas A., Tognoni G. and Barbui T. **W. Weber-Stadelmann** as a ECLAP investigator: Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. *J Clin Oncol* 23 : 2224-2232, 2005.
132. Maillet P., Chappuis P.O., Khoshbeen-Boudal M., Sciretta V., Sappino A.P. ; SIAK Network for Cancer Predisposition Testing and Counseling. **Weber W.** as a member of the network: Twenty-three novel BRCA 1 and BRCA 2 sequence variations identified in a cohort of Swiss breast and ovarian cancer families. *Cancer Genet Cytogenet.* 169 : 62-68, 2006.
133. More H., Humar B., **Weber W.**, Ward R., Christian A., Lintott c., Graziano F., Ruzzo A.M., Acosta E., Boman B., Harlan M., Ferreira P., Seruca R., Suriano G. and Guilford P. : Identification of seven novel germline mutations in the human E-cadherin (CDH1) gene. *Hum Mutat.* 28: 203-212, 2007.
134. **Walter Weber:** BRCA 1 and taxanes. *Hereditary Cancer in Clinical Practice* 5: 141, 2007.

135. Linger R., Dudakia D. Huddart R. and 34 coauthors (**Weber W.** as a coauthor): Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors. *Genes Chromosomes Cancer* 47: 247-252, 2008.
136. Mai P.L., Friedlander M., Tucker K. and 30 coauthors (**Weber W.** as a coauthor): The International Testicular Cancer Linkage Consortium: A clinico-pathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. *Urol Oncol.* 28 : 492-499, 2010.
137. Landin J. and **Weber W.** : Etiological observations in seven patients with pancreatic neuroendocrine tumors (PNETs). *In vivo* 30 : 147-148, 2016.
138. **Weber W.** and Weber S.S. : Etiological observations in 36 patients with Hodgkin's lymphoma. *Anticancer Research* 39 : 6859-6862, 2019.
139. Ritter M., Paradiso V., Widmer P., Garofoli A., Quagliata L., Eppenberger-Castori S., Soysal S.D., Muenst S., Ng C.K.Y., Piscuoglio S., **Weber W.** and Weber W.P. : Identification of somatic mutations in thirty-year-old serum cell-free DNA from patients with breast cancer : a feasibility study. *Clinical Breast Cancer* 20 : 413-421, 2020.
140. Boyle P., Autier P., Bartelink H. and 39 coauthors (**Weber W.** as a coauthor) European Code Against Cancer and scientific justification: third version (2003). *Ann Oncol* 14: 973-1005, 2003.
141. Heidinger M., Egle D., Piscuoglio S., Navarro-Aguadero M.A., Sanchez S., Hergueta-Redondo M., Gallardo M., Barrio S., García-Peláez B., Molina-Vila M.A., Maggi N., Eller R.S., Loesch J.M., Alborelli I., Peinado H., **Weber W.** and Weber W.P.: Extracellular vesicle DNA extraction and sequencing in ancient serum samples from patients with breast cancer. *Anticancer Research* 44: 2981-2988, 2024.